Skip to main content

Table 1 Self-reported participant socio demographicsa

From: Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study

Participants a

N = 10 (%); M ± SD

Age

54.71 (± 7.79)

Years on iOAT b

10.86 (± 2.17)

Type of Injectable Take-Home Medication

 

 Diacetylmorphine

9 (90)

 Hydromorphone

1 (10)

Race

 White/Caucasian

10 (100)

Born in Canada

10 (100)

Gender

 Female

2 (20)

 Male

8 (80)

Education

 Up to Grade 7

1 (10)

 Up to Grade 11

2 (20)

 Some College/University

5 (50)

 College/University Diploma

2 (20)

Disabled

8 (80)

Housed

10 (100)

Partnered

2 (20)

Has Children

6 (60)

  1. aOne client was part of the take-home program until his carry doses were reassessed and discontinued. He declined to be a part of this study
  2. bData only available for 7 participants